TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14523040

Group type: EXPERIMENTAL
Intervention: anti-IL-5 monoclonal antibody (mepolizumab)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 10962766

Group type: EXPERIMENTAL
Intervention: 12-session cognitive behavioral therapy (CBT)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: four‐session motivational enhancement therapy (MET)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: 12-session Twelve‐Step facilitation (TSF)
Number of subjects: 279
Study: 8905281

Group type: EXPERIMENTAL
Intervention: Membrane oxygenation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bubble oxygenation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 1653883

Group type: EXPERIMENTAL
Intervention: Lisinopril (L) 10, 20, or 40 mg per day
Number of subjects: 91

Group type: COMPARATOR
Intervention: Captopril (C) 25, 50, or 100 mg per day
Number of subjects: 91
Study: 6626903

Group type: EXPERIMENTAL
Intervention: Preoperative hibiscrub shower
Number of subjects: 94

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 94
Study: 31516558

Group type: EXPERIMENTAL
Intervention: Foot Cast (FC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Short Leg Cast (SLC)
Number of subjects: 72
Study: 29767459

Group type: EXPERIMENTAL
Intervention: Patiromer 8.4-33.6 g divided twice daily
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 304
Study: 27599871

Group type: EXPERIMENTAL
Intervention: Sulcardine sulfate 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulcardine sulfate 400 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulcardine sulfate 800 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulcardine sulfate 400 mg (fed)
Number of subjects: 10
Study: 26181091

Group type: EXPERIMENTAL
Intervention: 14 pills of study drug (150 microgram levonorgestrel and 30 microgram ethinyl estradiol combined OCPs)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: OCPs
Number of subjects: 32
Study: 24018647

Group type: EXPERIMENTAL
Intervention: Intensive glucose management strategy aiming at plasma glucose level of 85 to 110 mg/dL using intravenous insulin
Number of subjects: 294

Group type: COMPARATOR
Intervention: Conventional expectative glucose management
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Intensive glucose management strategy
Number of subjects: 294
Study: 20919767

Group type: EXPERIMENTAL
Intervention: TBI group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18937673

Group type: EXPERIMENTAL
Intervention: Bolus Wizard (phase A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional insulin dosing method (phase B)
Number of subjects: 36
Study: 16144800

Group type: EXPERIMENTAL
Intervention: BE-8 infusion (anti-IL-6 monoclonal antibody)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Melphalan 220 mg/m2 plus dexamethasone with BE-8 infusion
Number of subjects: 219

Group type: COMPARATOR
Intervention: Melphalan 200 mg/m2 and dexamethasone without BE-8 infusion
Number of subjects: 219
Study: 12747286

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment combined with folic acid supplementation (1 mg/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Methotrexate (MTX) treatment combined with placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: JIA patients
Number of subjects: 17
Study: 11053073

Group type: EXPERIMENTAL
Intervention: 25 mg hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher doses or long acting triamcinolone
Number of subjects: 0
Study: 8823699

Group type: EXPERIMENTAL
Intervention: ECO (combined cognitive/educational intervention)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: EDI (group education plus group discussion)
Number of subjects: 131

Group type: COMPARATOR
Intervention: WLC (waiting list control)
Number of subjects: 131
Study: 7955939

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg kg‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No caffeine (control)
Number of subjects: 10
Study: 3304372

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29856269

Group type: EXPERIMENTAL
Intervention: Active TENS and CJM
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo TENS and CJM
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo TENS and Active CJM
Number of subjects: 144

Group type: COMPARATOR
Intervention: Active TENS and Placebo CJM
Number of subjects: 144
Study: 27267349

Group type: EXPERIMENTAL
Intervention: Bioactive glass (NovaBone) bone graft putty material
Number of subjects: 15

Group type: COMPARATOR
Intervention: Platelet rich fibrin (PRF)
Number of subjects: 15
Study: 24469238

Group type: EXPERIMENTAL
Intervention: 2-year oral health fluoride varnish-oral health promotion intervention
Number of subjects: 1016

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 1016
Study: 22640000

Group type: EXPERIMENTAL
Intervention: PCI combined with TCA 20%
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 1540 nm fractional laser
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined alternating sessions of PCI and TCA 20% with 1540 nm fractional laser
Number of subjects: 39
Study: 22846371

Group type: EXPERIMENTAL
Intervention: Nizatidine (300 mg/day) for 4 weeks
Number of subjects: 30
Study: 20539245

Group type: EXPERIMENTAL
Intervention: Phytoestrogens (PHY)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 21
Study: 17658395

Group type: EXPERIMENTAL
Intervention: Late intensification course (high-dose cytarabine and methotrexate)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Hybrid treatment protocol
Number of subjects: 482
Study: 16254764

Group type: EXPERIMENTAL
Intervention: Self-Efficacy Questionnaire for Depression in Adolescents (SEQ-DA)
Number of subjects: 130
Study: 15552071

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 18
Study: 10613649

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIII (Recombinate) at a dose of 50 IU/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIII (Recombinate) using concentrate standard
Number of subjects: 30
Study: 8776185

Group type: EXPERIMENTAL
Intervention: Coated circuit with low systemic heparinization (200 IU/kg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Uncoated circuit with higher systemic heparinization (300 IU/kg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Coated group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Uncoated group
Number of subjects: 101
Study: 1375679

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg oral dose)
Number of subjects: 20
Study: 6330871

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg at night)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 47
Study: 29912763

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 510
Study: 29171140

Group type: EXPERIMENTAL
Intervention: GAD-Alum (20 μg, 2 injections, 30 days apart)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25119067

Group type: EXPERIMENTAL
Intervention: Online Parent Information and Support (OPIS) application
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group without access to OPIS
Number of subjects: 20
Study: 25265549

Group type: EXPERIMENTAL
Intervention: School‐based intervention with added parent training component
Number of subjects: 52

Group type: COMPARATOR
Intervention: School‐based program focused solely on intervening with the adolescent (no parental involvement)
Number of subjects: 52
Study: 22834281

Group type: EXPERIMENTAL
Intervention: Glutamine (20% solution N(2)‐L‐alanine‐L‐glutamine, 'Dipeptiven' Fresenius Kabi, Germany); 0.4 g/kg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl solution)
Number of subjects: 50
Study: 20819489

Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy (CRT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 158
Study: 17932240

Group type: EXPERIMENTAL
Intervention: Telepsychiatry (TP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Same Room (SR)
Number of subjects: 38
Study: 16223396

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 11870934

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 100 mg only (G1)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Heparin infusion followed by 6 months of oral anticoagulation with coumadin (G2)
Number of subjects: 191
Study: 10563540

Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole od
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole od
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7569589

Group type: EXPERIMENTAL
Intervention: Early oral feeding (started as early as 6 hours postoperatively)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral feeding forbidden until spontaneous restoration of intestinal function
Number of subjects: 100
Study: 1329919

Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 6377801

Group type: EXPERIMENTAL
Intervention: progabide (24.3 mg/kg daily for 2 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: progabide
Number of subjects: 16
Study: 30747254

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg once per day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 29562763

Group type: EXPERIMENTAL
Intervention: Virtual Traveller (VT) intervention
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control (COM) group
Number of subjects: 219
Study: 27060535

Group type: EXPERIMENTAL
Intervention: Targeted therapeutic mild hypercapnia (TTMH) (PaCO2 50-55mmHg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Targeted normocapnia (TN) (PaCO2 35-45mmHg)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Hospital mortality
Number of subjects: 86
Study: 24284515

Group type: EXPERIMENTAL
Intervention: Extravesical ureteroneocystostomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravesical ureteroneocystostomy
Number of subjects: 200
Study: 22149445

Group type: EXPERIMENTAL
Intervention: Prostacyclin (0.5 ng kg(-1) min(-1))
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (ICP-targeted therapy without prostacyclin)
Number of subjects: 48
Study: 20172539

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic lobectomy
Number of subjects: 752
Study: 17636186

Group type: EXPERIMENTAL
Intervention: Low-intensity VKA treatment (target INR 2.5) plus aspirin (100 mg/day) for the first six months (Group A)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard-intensity VKA treatment (target INR 3.7) (Group B)
Number of subjects: 198
Study: 15662502

Group type: EXPERIMENTAL
Intervention: CF 540 cutoff filter
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CF 580 cutoff filter
Number of subjects: 22
Study: 12005179

Group type: EXPERIMENTAL
Intervention: Intravenous bisphosphonates
Number of subjects: 27
Study: 10191743

Group type: EXPERIMENTAL
Intervention: Impaction-grafting with demineralized bone matrix (DBM)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Impaction-grafting with fresh cancellous bone graft
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-grafted controls
Number of subjects: 25
Study: 8678266

Group type: COMPARATOR
Intervention: Thiopentone 4‐6 mg/kg i.v., halothane 0.8‐1.5%, N2O‐‐O2 2:1, no opioids, droperidol 75 micrograms/kg i.v. (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol 2‐3 mg/kg i.v., propofol 6‐9 mg/kg.h, alfentanil 30 micrograms/kg.h, N2O‐O2 2:1, no antiemetics (Group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Similar to Group 2, but ventilation with air and O2 2:1 (Group 3)
Number of subjects: 90
Study: 2354096

Group type: EXPERIMENTAL
Intervention: Suxamethonium after sub-paralysing dose of tubocurarine (0.05 mg kg-1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Suxamethonium after paralysing dose of atracurium (0.5 mg kg-1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Suxamethonium alone (saline control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg kg-1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tubocurarine (0.05 mg kg-1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 21
Study: 361313

Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 30658228

Group type: EXPERIMENTAL
Intervention: Peripheral venous and arterial devices
Number of subjects: 7669

Group type: EXPERIMENTAL
Intervention: Central devices
Number of subjects: 7669

Group type: EXPERIMENTAL
Intervention: Peripheral arterial catheters
Number of subjects: 7669

Group type: EXPERIMENTAL
Intervention: Radial insertion
Number of subjects: 7669

Group type: EXPERIMENTAL
Intervention: Basilic insertion
Number of subjects: 7669

Group type: EXPERIMENTAL
Intervention: Poor skin integrity
Number of subjects: 7669
Study: 28719609

Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 46

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 46
Study: 25776116

Group type: EXPERIMENTAL
Intervention: RPMS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study: 23347435

Group type: EXPERIMENTAL
Intervention: Intensive cabergoline treatment (weekly increase by 1 mg per week followed by 4 weekly escalation)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional cabergoline treatment (4 weekly escalation by 0.5 mg per week)
Number of subjects: 38
Study: 21334655

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg alone
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1505
Study: 19210150

Group type: EXPERIMENTAL
Intervention: Amlodipine/Olmesartan Medoxomil (AML/OM) 10/40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine/Valsartan (AML/VAL) 10/320 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine (AML)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan (VAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olmesartan Medoxomil (OM)
Number of subjects: 0
Study: 16729783

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide with salbutamol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Salbutamol alone (control)
Number of subjects: 74
Study: 15180672

Group type: EXPERIMENTAL
Intervention: Self-modeling regression (SEMOR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time warping procedures
Number of subjects: 0
Study: 11883126

Group type: EXPERIMENTAL
Intervention: Multilumen venous catheters
Number of subjects: 100
Study: 9215826

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with methotrexate (30 mg/m2 on days 1, 15, and 22), vinblastine (3 mg/m2 on days 2, 15, and 22), doxorubicin (30 mg/m2 on day 2), and cisplatin (70 mg/m2 on day 2)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Single‐agent cisplatin (70 mg/m2 on day 1)
Number of subjects: 255
Study: 8481018

Group type: COMPARATOR
Intervention: Acyclovir suppressive therapy (400 mg twice daily)
Number of subjects: 1100
Study: 3436489

Group type: EXPERIMENTAL
Intervention: Physical training for up to 2 years
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 8
Study: 29667217

Group type: EXPERIMENTAL
Intervention: False-positive PSA test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: False-positive digital rectal exam (DRE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biopsy follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incidence and mortality rates
Number of subjects: 0
Study: 26849263

Group type: EXPERIMENTAL
Intervention: Be Well, Work Well workplace intervention
Number of subjects: 0
Study: 25895964

Group type: EXPERIMENTAL
Intervention: Oral hygiene and dietary counseling
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Oral hygiene and fluoride varnish application at 4, 8, and 12 months
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Oral hygiene and tooth mousse applied by parents twice a day for 12 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: No preventive intervention (control group)
Number of subjects: 140
Study: 23086138

Group type: EXPERIMENTAL
Intervention: TAK-875 6.25 mg
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: TAK-875 12.5 mg
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: TAK-875 25 mg
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: TAK-875 50 mg
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: TAK-875 100 mg
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: TAK-875 200 mg
Number of subjects: 396

Group type: COMPARATOR
Intervention: Glimepiride 1 mg
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study: 20507968

Group type: EXPERIMENTAL
Intervention: Increased end-expiratory lung volume (EELV)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increased genioglossus (GG) activity
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increased EELV and increased GG
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 15
Study: 18669462

Group type: EXPERIMENTAL
Intervention: Amifostine (600 mg/m2/dose) administered as a bolus immediately before and 3 hours into the cisplatin infusion
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 62
Study: 15815566

Group type: EXPERIMENTAL
Intervention: Didactic educational intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Registered Nurses (RNs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Registered Nurses (non-RNs)
Number of subjects: 0
Study: 14607206

Group type: EXPERIMENTAL
Intervention: Moxonidine SR (1.5 mg BID)
Number of subjects: 1934

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1934

Group type: EXPERIMENTAL
Intervention: Moxonidine SR
Number of subjects: 1934
Study: 10544625

Group type: EXPERIMENTAL
Intervention: 20 mSRT (20‐m progressive shuttle run test)
Number of subjects: 1317

Group type: EXPERIMENTAL
Intervention: Lower limb injury
Number of subjects: 1317
Study: 8686973

Group type: EXPERIMENTAL
Intervention: 150 mg of lamivudine twice daily plus 200 mg of zidovudine three times daily (low-dose lamivudine group)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: 300 mg of lamivudine twice daily plus 200 mg of zidovudine three times daily (high-dose lamivudine group)
Number of subjects: 254

Group type: COMPARATOR
Intervention: 0.75 mg of zalcitabine plus 200 mg of zidovudine three times daily (zalcitabine group)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: 150 mg of lamivudine plus zidovudine
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: 300 mg of lamivudine plus zidovudine
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 254
Study: 2051759

Group type: EXPERIMENTAL
Intervention: Work-related injuries in manufacturing industries and agriculture/forestry/fishing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Service sector workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food and fish processing industry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical engineering industry
Number of subjects: 0
Study: 6337710

Group type: EXPERIMENTAL
Intervention: Procarbazine
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: BCNU
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: BCNU plus high-dose methylprednisolone
Number of subjects: 609

Group type: COMPARATOR
Intervention: High-dose methylprednisolone
Number of subjects: 609
Study: 31851710

Group type: COMPARATOR
Intervention: Two-finger technique 1 (TFT1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Two-finger technique 2 (TFT2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pinch technique 1 (PT1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pinch technique 2 (PT2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plate-assisted technique (PAT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: TFT2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PT1
Number of subjects: 50

Group type: COMPARATOR
Intervention: TFT1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PAT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PT2
Number of subjects: 50
Study: 29216820

Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 0.2 μg·kg-1·hr-1
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 0.5 μg·kg-1·hr-1
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 0.8 μg·kg-1·hr-1
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All groups (0.2, 0.5, 0.8 μg·kg-1·hr-1)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Low-dose infusion of sufentanil
Number of subjects: 49
Study: 26719230

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg) added to 500 mg/m² pemetrexed and 75 mg/m² cisplatin (PCB)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Cisplatin plus pemetrexed (PC)
Number of subjects: 448
Study: 24995954

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Butamirate (various doses)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 22747949

Group type: EXPERIMENTAL
Intervention: Intervention program at the workplace including integrated care and participatory workplace intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention program at the workplace
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care by rheumatologist (Control)
Number of subjects: 0